[Pharmacotherapy for Schizophrenia]

Overview

Journal Nervenarzt

Specialty Neurology

Date 2006 Nov 4

PMID 17082927

Authors

W W Fleischhacker

W Hummer

Affiliations

Soon will be listed here.

Abstract

The management of schizophrenia patients remains one of the great challenges in psychiatry. Despite the undisputed effectiveness of antipsychotic drugs, patients and their physicians still face considerable difficulties mainly related to incomplete or lacking treatment response and the inability to predict the individual efficacy and tolerability. In this manuscript we review the key elements of pharmacological treatment of this disorder, encompassing acute and long-term management as well as specific management problems ranging from acutely violent patients to treatment-resistant subjects. Along with general treatment principles, the document provides specific information regarding efficacy and safety features of antipsychotics. Many of the currently available treatment recommendations/guidelines are based on the evidence reviewed here. This review is meant to serve as a guide for clinicians involved in managing schizophrenia, whether in a psychiatric hospital setting or as family physicians in private practice.

References

Fleischhacker W . Clozapine: a comparison with other novel antipsychotics. J Clin Psychiatry. 1999; 60 Suppl 12:30-4. View

Baldessarini R, Cohen B, Teicher M . Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988; 45(1):79-91. DOI: 10.1001/archpsyc.1988.01800250095013. View

Volavka J, Cooper T, Czobor P, Lindenmayer J, Citrome L, Mohr P . High-dose treatment with haloperidol: the effect of dose reduction. J Clin Psychopharmacol. 2000; 20(2):252-6. DOI: 10.1097/00004714-200004000-00020. View

Citrome L, Volavka J . The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Postgrad Med. 2004; 116(4):49-51, 55-9, 63. DOI: 10.3810/pgm.2004.10.1601. View

Hirsch S, Barnes T . Clinical use of high-dose neuroleptics. Br J Psychiatry. 1994; 164(1):94-6. DOI: 10.1192/bjp.164.1.94. View

Raskin S, Katz G, Zislin Z, Knobler H, Durst R . Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand. 2000; 101(4):334-6. View

Beasley C, Dellva M, Tamura R, Morgenstern H, Glazer W, Ferguson K . Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry. 1999; 174:23-30. DOI: 10.1192/bjp.174.1.23. View

Zimbroff D, Kane J, Tamminga C, Daniel D, Mack R, Wozniak P . Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry. 1997; 154(6):782-91. DOI: 10.1176/ajp.154.6.782. View

Davis J, Matalon L, Watanabe M, Blake L, Metalon L corrected to Matalon L . Depot antipsychotic drugs. Place in therapy. Drugs. 1994; 47(5):741-73. DOI: 10.2165/00003495-199447050-00004. View

10.

GILBERT P, Harris M, McAdams L, Jeste D . Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995; 52(3):173-88. DOI: 10.1001/archpsyc.1995.03950150005001. View

11.

Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R . [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group]. Encephale. 2002; 28(6 Pt 1):552-62. View

12.

Van Putten T, MAY P, Marder S, Wittmann L . Subjective response to antipsychotic drugs. Arch Gen Psychiatry. 1981; 38(2):187-90. DOI: 10.1001/archpsyc.1981.01780270073010. View

13.

Ballas C, Yang C, OReardon J, Ballas P, Baldassano C . Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother. 2005; 4(2):179-86. DOI: 10.1586/14737175.4.2.179. View

14.

Lindstrom E, Eriksson B, HELLGREN A, von Knorring L, Eberhard G . Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther. 1995; 17(3):402-12. DOI: 10.1016/0149-2918(95)80105-7. View

15.

Kane J, Aguglia E, Altamura A, Ayuso Gutierrez J, Brunello N, Fleischhacker W . Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998; 8(1):55-66. DOI: 10.1016/s0924-977x(97)00045-x. View

16.

Lehman A, Kreyenbuhl J, Buchanan R, Dickerson F, Dixon L, Goldberg R . The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004; 30(2):193-217. DOI: 10.1093/oxfordjournals.schbul.a007071. View

17.

Schooler N, Keith S, Severe J, Matthews S, Bellack A, Glick I . Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry. 1997; 54(5):453-63. DOI: 10.1001/archpsyc.1997.01830170079011. View

18.

Swainston Harrison T, Goa K . Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs. 2004; 18(2):113-32. DOI: 10.2165/00023210-200418020-00005. View

19.

Glick I, Marder S . Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005; 66(5):638-41. DOI: 10.4088/jcp.v66n0515. View

20.

Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker W . Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry. 1999; 156(4):631-3. DOI: 10.1176/ajp.156.4.631. View